^
Association details:
Biomarker:FGFR mutation
Cancer:Breast Cancer
Drug:Tasfygo (tasurgratinib) (FGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models

Excerpt:
To evaluate the effect of E7090 on survival, we established a lung metastasis model using 4T1, a mouse breast cancer cell line...Daily administration of E7090 significantly prolonged the survival of mice in the 12.5 to 50 mg/kg dosing groups.
DOI:
10.1158/1535-7163.MCT-16-0261